5G-PEARL: Paxalisib in Malignant Brain Tumours — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

5G-PEARL: Paxalisib in Malignant Brain Tumours — Stella

Recruiting

Back to Malignant Primary Gliomas trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United Kingdom

Royal Marden NHS Foundation Trust, Sutton

Key details

Phase

Early testing / Safety & dosing

Sponsor

Institute of Cancer Research, United Kingdom

Collaborators

Minderoo Foundation, Kazia Therapeutics Limited

Enrollment target

~64 participants

Started

January 2026

Primary completion

January 2029

Age range

16 Years and older

Last updated February 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov